https://scholars.lib.ntu.edu.tw/handle/123456789/631865
標題: | Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial | 作者: | Suzuki, Kenshi Min, Chang-Ki Kim, Kihyun Lee, Je-Jung Shibayama, Hirohiko Ko, Po-Shen SHANG-YI HUANG Li, Sin-Syue Ding, Bifeng Khurana, Monica Iida, Shinsuke |
關鍵字: | Asian population; CANDOR trial; Carfilzomib; Daratumumab; Relapsed refractory multiple myeloma | 公開日期: | 十二月-2021 | 出版社: | SPRINGER JAPAN KK | 卷: | 114 | 期: | 6 | 起(迄)頁: | 653 | 來源出版物: | International journal of hematology | 摘要: | Due to increasing use of frontline lenalidomide, effective and safe lenalidomide-free therapies for relapsed/refractory multiple myeloma (RRMM) are needed in Asia. This subgroup analysis of phase 3 CANDOR study evaluated efficacy and safety of KdD vs Kd in Asian patients with RRMM. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/631865 | ISSN: | 0925-5710 | DOI: | 10.1007/s12185-021-03204-9 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。